MAPS Public Benefit Corporation (MAPS PBC) is the ‘benefit above profit’ corporation that is fully owned by MAPS.
MAPS PBC was established in 2014 and is a hybrid between a non-profit and for-profit business. It aims for profit, pays taxes, but aims to serve the public to the fullest.
In December 2021, MAPS and Vine Ventures announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD. This model fully maintains both MAPS’ nonprofit mission and governance and MAPS PBC public benefit drug development and post-approval activities.
“MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics prioritizing public benefit above profit. Founded in 2014, MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS) a 501(c)(3) nonprofit.”
The MAPS therapy training program, among other things, is a thing that MAPS PBC does.
- Numinus and MAPS Public Benefit Corporation Announce Collaboration Agreement to Seek Approval of MDMA-Assisted Psychotherapy for PTSD Single-Arm, Open-Label Trial (press release, December 2020)
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Related Course(s)MDMA Therapy Training Program
The course is an in-depth training into the practice of MDMA-Assisted Psychotherapy, with curriculum based on decades of clinical experience.
Company NewsWesana Health Commits Funding of $1.5 Million To Support MAPS’ Research Pipeline (Press Release, 14 September 2021)
In September 2021, Wesana committed $1.5 million to fund MAPS PBC in an effort to do more research on traumatic brain injury with MDMA.
Novel PTSD Treatment Advances Toward Regulatory Evaluation with New Collaboration (MAPS, 27 June 2022)